Zealand Pharma: partner granted 'breakthrough' designation
(CercleFinance.com) - Danish biotech firm Zealand Pharma said on Tuesday that the US Food and Drug Administration (FDA) has granted breakthrough device designation for a blood-sugar control system developed by its US partner Beta Bionics.
The "iLet Bionic Pancreas System," a pocket-sized, wearable investigational medical device has been designed to control blood-sugar levels, with configurations with most insulin analogs, including Zealand Pharma's dasiglucagon.
Zealand Pharma said it now plans to advance dasiglucagon in the bihormonal artificial pancreas system into a Phase 3 development trial.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The "iLet Bionic Pancreas System," a pocket-sized, wearable investigational medical device has been designed to control blood-sugar levels, with configurations with most insulin analogs, including Zealand Pharma's dasiglucagon.
Zealand Pharma said it now plans to advance dasiglucagon in the bihormonal artificial pancreas system into a Phase 3 development trial.
Copyright (c) 2019 CercleFinance.com. All rights reserved.